[1] Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study [J]. JAMA Oncol, 2019, 5(12): 1749-1768. DOI: 10.1001/jamaoncol.2019.2996.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3] Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007) [J]. Gastric Cancer, 2018, 21(1):144-154. DOI: 10.1007/s10120-017-0716-7.
[4] Li Z, Lei H, Luo M, et al. DNA methylation downregulated miR-10b acts as a tumor suppressor in gastric cancer [J]. Gastric Cancer, 2015, 18(1):43-54. DOI: 10.1007/s10120-014-0340-8.
[5] Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis [J]. Stat Appl Genet Mol Biol, 2005, 4: Article17. DOI: 10.2202/1544-6115.1128.
[6] Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis [J]. BMC Bioinformatics, 2008, 9: 559. DOI: 10.1186/1471-2105-9-559.
[7] van Dam S, Võsa U, van der Graaf A, et al. Gene co-expression analysis for functional classification and gene-disease predictions [J]. Brief Bioinform, 2018, 19(4): 575-592. DOI: 10.1093/bib/bbw139.
[8] Li A, Horvath S. Network neighborhood analysis with the multi-node topological overlap measure [J]. Bioinformatics, 2007, 23(2): 222-231. DOI: 10.1093/bioinformatics/btl581.
[9] Yip AM, Horvath S. Gene network interconnectedness and the generalized topological overlap measure [J]. BMC Bioinformatics, 2007, 8: 22. DOI: 10.1186/1471-2105-8-22.
[10] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium [J]. Nat Genet, 2000, 25(1): 25-29. DOI:10.1038/75556.
[11] Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs [J]. Nucleic Acids Res, 2017, 45(D1): D353-D361. DOI: 10.1093/nar/gkw1092.
[12] Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses [J]. Nucleic Acids Res, 2017, 45(W1): W98-W102. DOI: 10.1093/nar/gkx247.
[13] Kunzke T, Balluff B, Feuchtinger A, et al. Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome [J]. Oncotarget, 2017, 8(40): 68012-68025. DOI: 10.18632/oncotarget.19137.
[14] Nienhüser H, Schmidt T. Angiogenesis and anti-angiogenic therapy in gastric cancer [J]. Int J Mol Sci, 2017, 19(1): 43. DOI:10.3390/ijms19010043.
[15] Feitelson MA, Arzumanyan A, Kulathinal RJ, et al. Sustained proliferation in cancer: mechanisms and novel therapeutic targets [J]. Semin Cancer Biol, 2015, 35 Suppl: S25-S54. DOI: 10.1016/j.semcancer.2015.02.006.
[16] Hu M, Zhu S, Xiong S, et al. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review) [J]. Oncol Rep, 2019, 41(3): 1439-1454. DOI:10.3892/or.2019.6962.
[17] Fattahi S, Amjadi-Moheb F, Tabaripour R, et al. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond [J]. Life Sci, 2020, 262: 118513. DOI: 10.1016/j.lfs.2020.118513.
[18] Du F, Sun L, Chu Y, et al. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways [J]. Cancer Commun (Lond), 2018, 38(1): 45. DOI: 10.1186/s40880-018-0315-y.
[19] Magnelli L, Schiavone N, Staderini F, et al. MAP kinases pathways in gastric cancer [J]. Int J Mol Sci, 2020, 21(8): 2893. DOI: 10.3390/ijms21082893.
[20] Dong C, Sun J, Ma S, et al. K-ras-ERK1/2 down-regulates H2A.XY142ph through WSTF to promote the progress of gastric cancer [J]. BMC Cancer, 2019, 19(1): 530. DOI: 10.1186/s12885-022-10052-1.
[21] Li W, Han F, Fu M, et al. High expression of VCAN is an independent predictor of poor prognosis in gastric cancer [J]. J Int Med Res, 2020, 48(1): 300060519891271. DOI: 10.1177/0300060519891271.
[22] Theocharis AD, Vynios DH, Papageorgakopoulou N, et al. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma [J]. Int J Biochem Cell Biol, 2003, 35(3): 376-390. DOI: 10.1016/s1357-2725(02)00264-9.
[23] Xu Y, Chen W, Liang J, et al. The miR-1185-2-3p-GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1 [J]. J Exp Clin Cancer Res, 2021, 40(1): 47. DOI: 10.1186/s13046-020-01767-9.
[24] Kim WT, Mun JY, Baek SW, et al. Secretory SERPINE1 expression is increased by antiplatelet therapy, inducing MMP1 expression and increasing colon cancer metastasis [J]. Int J Mol Sci, 2022, 23(17): 9596. DOI: 10.3390/ijms23179596.
[25] Teng F, Zhang JX, Chen Y, et al. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer [J]. Mol Oncol, 2021, 15(4):1234-1255. DOI: 10.1002/1878-0261.12911.
[26] Gao LM, Wang F, Zheng Y, et al. Roles of fibroblast activation protein and hepatocyte growth factor expressions in angiogenesis and metastasis of gastric cancer [J]. Pathol Oncol Res, 2019, 25(1): 369-376. DOI: 10.1007/s12253-017-0359-3.
[27] Ding X, Xi W, Ji J, et al. HGF derived from cancer-associated fibroblasts promotes vascularization in gastric cancer via PI3K/AKT and ERK1/2 signaling [J]. Oncol Rep, 2018, 40(2): 1185-1195. DOI: 10.3892/or.2018.6500.
[28] Yi X, Zheng X, Xu H, et al. IGFBP7 and the tumor immune landscape: a novel target for immunotherapy in bladder cancer [J]. Front Immunol, 2022, 13: 898493. DOI: 10.3389/fimmu.2022.898493.
[29] Akiel M, Guo C, Li X, et al. IGFBP7 deletion promotes hepatocellular carcinoma [J]. Cancer Res, 2017, 77(15): 4014-4025. DOI:10.1158/0008-5472.CAN-16-2885.
[30] Artico LL, Laranjeira ABA, Campos LW, et al. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia [J]. Blood Adv, 2021, 5(18): 3633-3646. DOI: 10.1182/bloodadvances.2020003627.
[31] Zhao Q, Zhao R, Song C, et al. Increased IGFBP7 expression correlates with poor prognosis and immune infiltration in gastric cancer [J]. J Cancer, 2021, 12(5): 1343-1355. DOI: 10.7150/jca.50370.
[32] Li D, Xia L, Huang P, et al. Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2/FGFR1/PI3K/AKT axis [J]. Cell Death Discov, 2023, 9(1): 17. DOI: 10.1038/s41420-023-01336-x.
[33] Ge H, Yan Y, Tian F, et al. LINC00922 promotes deterioration of gastric cancer [J]. PLoS One, 2022, 17(5): e0267798. DOI: 10.1371/journal.pone.0267798.
|